Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + temozolomide + bevacizumab
- Development stage
- Discontinued
- Lead developer
- University of Arizona
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
This combination regimen consists of nab-paclitaxel (an albumin-bound nanoparticle formulation of paclitaxel), temozolomide (an oral alkylating chemotherapy agent), and bevacizumab (a monoclonal antibody targeting VEGF). It was investigated by the University of Arizona in a Phase 1/2 pilot study (NCT02065466) specifically for the treatment of patients with metastatic melanoma and newly diagnosed brain metastases. Temozolomide was included for its ability to cross the blood-brain barrier and exert cytotoxic effects on intracranial lesions, while bevacizumab was utilized to inhibit tumor angiogenesis and potentially reduce peritumoral edema. Nab-paclitaxel provides systemic microtubule-stabilizing activity with a favorable toxicity profile compared to solvent-based paclitaxel.
- Brand names
- AbraxaneTemodarAvastin
- Other names
- temozolomide-University of Arizona-melanoma (metastatic)UA melanoma regimen
02
Targets
Beyond the preview
Go deeper on nab-paclitaxel + temozolomide + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + temozolomide + bevacizumab.